Literature DB >> 18292238

A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin.

Mei Hui Liu1, Jun Li, Ping Shen, B Husna, E Shyong Tai, E L Yong.   

Abstract

Peroxisome proliferator-activated receptor-alpha (PPARalpha) is a central regulator of lipid metabolism. Fibrate drugs act on PPARalpha to modulate dyslipidemias. A natural variant (V227A) affecting the PPARalpha hinge region was associated with perturbations in blood lipid levels in Asian populations. In this study, we investigated the functional significance of the V227A substitution. The variant significantly attenuated PPARalpha-mediated transactivation of the cytochrome P450 4A6 and mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS2) genes in the presence of fibrate ligands. Screening of a panel of PPARalpha coregulators revealed that V227A enhanced recruitment of the nuclear corepressor NCoR. Transactivation activity of V227A could be restored by silencing NCoR or by inhibition of its histone deacetylase activity. Deletion studies indicated that PPARalpha interacted with NCoR receptor-interacting domain 1 (ID1) but not ID2 or ID3. These interactions were dependent on the intact consensus nonapeptide nuclear receptor interaction motif in NCoR ID1 and were enhanced by the adjacent 24 N-terminal residues. Novel corepressor interaction determinants involving PPARalpha helices 1 and 2 were identified. In hepatic cells, the V227A substitution stabilized PPARalpha/NCoR interactions and caused defective release of NCoR in the presence of agonists on the HMGCS2 promoter. These results provide the first indication that defective function of a natural PPARalpha variant was due, at least partially, to increased corepressor binding. Our data suggest that the PPARalpha/NCoR interaction is physiologically relevant and can produce a discernable phenotype when the magnitude of the interaction is altered by a naturally occurring variation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292238      PMCID: PMC5419521          DOI: 10.1210/me.2007-0547

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  61 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways.

Authors:  J J Voegel; M J Heine; M Tini; V Vivat; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

3.  Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions.

Authors:  C J Loy; K S Sim; E L Yong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

4.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

Authors:  T A Jackson; J K Richer; D L Bain; G S Takimoto; L Tung; K B Horwitz
Journal:  Mol Endocrinol       Date:  1997-06

5.  A canonical structure for the ligand-binding domain of nuclear receptors.

Authors:  J M Wurtz; W Bourguet; J P Renaud; V Vivat; P Chambon; D Moras; H Gronemeyer
Journal:  Nat Struct Biol       Date:  1996-01

6.  The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes.

Authors:  R B Vega; J M Huss; D P Kelly
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 7.  International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Authors:  Liliane Michalik; Johan Auwerx; Joel P Berger; V Krishna Chatterjee; Christopher K Glass; Frank J Gonzalez; Paul A Grimaldi; Takashi Kadowaki; Mitchell A Lazar; Stephen O'Rahilly; Colin N A Palmer; Jorge Plutzky; Janardan K Reddy; Bruce M Spiegelman; Bart Staels; Walter Wahli
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

8.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

Authors:  A Sapone; J M Peters; S Sakai; S Tomita; S S Papiha; R Dai; F K Friedman; F J Gonzalez
Journal:  Pharmacogenetics       Date:  2000-06

9.  The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis.

Authors:  Christine Yu; Kathleen Markan; Karla A Temple; Dianne Deplewski; Matthew J Brady; Ronald N Cohen
Journal:  J Biol Chem       Date:  2005-02-03       Impact factor: 5.157

10.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Authors:  S S Lee; T Pineau; J Drago; E J Lee; J W Owens; D L Kroetz; P M Fernandez-Salguero; H Westphal; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

View more
  11 in total

Review 1.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 2.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

Review 3.  PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

Authors:  Alejandra V Contreras; Nimbe Torres; Armando R Tovar
Journal:  Adv Nutr       Date:  2013-07-01       Impact factor: 8.701

Review 4.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

5.  SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR.

Authors:  Benoit Pourcet; Inés Pineda-Torra; Bruno Derudas; Bart Staels; Corine Glineur
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

Review 6.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

7.  Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment.

Authors:  Iwona Rudkowska; Mélanie Verreault; Olivier Barbier; Marie-Claude Vohl
Journal:  PPAR Res       Date:  2009-02-25       Impact factor: 4.964

8.  Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα.

Authors:  Ning Liang; Anastasius Damdimopoulos; Saioa Goñi; Zhiqiang Huang; Lise-Lotte Vedin; Tomas Jakobsson; Marco Giudici; Osman Ahmed; Matteo Pedrelli; Serena Barilla; Fawaz Alzaid; Arturo Mendoza; Tarja Schröder; Raoul Kuiper; Paolo Parini; Anthony Hollenberg; Philippe Lefebvre; Sven Francque; Luc Van Gaal; Bart Staels; Nicolas Venteclef; Eckardt Treuter; Rongrong Fan
Journal:  Nat Commun       Date:  2019-04-11       Impact factor: 14.919

Review 9.  Impact of PPAR-Alpha Polymorphisms-The Case of Metabolic Disorders and Atherosclerosis.

Authors:  Massimiliano Ruscica; Marco Busnelli; Enrico Runfola; Alberto Corsini; Cesare R Sirtori
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

10.  NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.

Authors:  Yaru Li; Mingming Chen; Yu Zhou; Chuanfeng Tang; Wen Zhang; Ying Zhong; Yadong Chen; Hong Zhou; Liang Sheng
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.